Overview
Drug discovery company developing non-hallucinogenic psychoplastogenic compounds that promote neural plasticity similar to psychedelics without the perceptual effects. Their TrkB-targeting molecules aim to treat depression, addiction, and neurological disorders.
More in Psychedelics
Latest industry news
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
A New Neurotech Startup Launches to Challenge Sam Altman's Merge Labs in the BCI Race
2026-10-10 · Industry
Butterfly Network Teams Up With Bridge Neurotech to Chase Ultrasound-Based Brain-Computer Interfaces
2026-10-09 · Industry
Paradromics Hits Four-Year Mark for Stable Neural Recording in Landmark BCI Durability Milestone
2026-10-08 · Research
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →